Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan V Boddy

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Cancer Chemotherapy and Pharmacology|June 14, 2016
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumoursSebastiaan C Goulooze, Peter Galettis, Alan V Boddy, et al.
Therapeutic Drug Monitoring|November 23, 2011
Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring--using doxorubicin as an exampleNina E Kontny, Georg Hempel, Joachim Boos, et al.
Cancer Chemotherapy and Pharmacology|January 19, 2006
Biliary excretion of etoposide in children with cancerGareth J Veal, Julie Errington, Huw D Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapyGirish Chinnaswamy, Julie Errington, Annabel Foot, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2016
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancerNicola Cresti, Joanne Lee, Emma Rourke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 24, 2010
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humansSophie E Rowbotham, Nicola A Illingworth, Ann K Daly, et al.
Clinical Pharmacokinetics|June 28, 2014
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancerChristopher R Hill, Michael Cole, Julie Errington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Cyclophosphamide metabolism in children with non-Hodgkin's lymphomaS Murray Yule, Lisa Price, Alex D McMahon, et al.
British Journal of Clinical Pharmacology|February 9, 2017
A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemiaJanna K Duong, Melanie J Griffin, Darren Hargrave, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2018
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidenceMelanie White-Koning, Caroline Osborne, Angelo Paci, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|June 14, 2016
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumoursSebastiaan C Goulooze, Peter Galettis, Alan V Boddy, et al.
Therapeutic Drug Monitoring|November 23, 2011
Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring--using doxorubicin as an exampleNina E Kontny, Georg Hempel, Joachim Boos, et al.
Cancer Chemotherapy and Pharmacology|January 19, 2006
Biliary excretion of etoposide in children with cancerGareth J Veal, Julie Errington, Huw D Thomas, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2011
Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapyGirish Chinnaswamy, Julie Errington, Annabel Foot, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2016
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancerNicola Cresti, Joanne Lee, Emma Rourke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 24, 2010
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humansSophie E Rowbotham, Nicola A Illingworth, Ann K Daly, et al.
Clinical Pharmacokinetics|June 28, 2014
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancerChristopher R Hill, Michael Cole, Julie Errington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Cyclophosphamide metabolism in children with non-Hodgkin's lymphomaS Murray Yule, Lisa Price, Alex D McMahon, et al.
British Journal of Clinical Pharmacology|February 9, 2017
A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemiaJanna K Duong, Melanie J Griffin, Darren Hargrave, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2018
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidenceMelanie White-Koning, Caroline Osborne, Angelo Paci, et al.
Pageof 9